<DOC>
	<DOCNO>NCT02945007</DOCNO>
	<brief_summary>The purpose study assess relative bioavailability 1 3 concept formulation JNJ-53718678 compare currently exist oral solution , assess effect food bioavailability 1 3 oral concept formulation JNJ-53718678 administer single oral dose 500 milligram ( mg ) healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Relative Oral Bioavailability Single Dose JNJ-53718678 Administered Oral Concept Formulation Compared Current Oral Solution Assess Effect Food Pharmacokinetics Oral Concept Formulation</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>At Screening , female participant must nonchildbearing potential define protocol Female participant must negative serum beta human chorionic gonadotropin ( betahCG ) pregnancy test Screening A male participant must sexually abstinent ( define refrain sexual intercourse Day 1 ( day dose ) 90 day study drug intake ) sexually active ( either heterosexual , include pregnant woman , homosexual ) must agree use barrier method contraception ( example , condom ) Day 1 ( day dose ) 90 day study drug intake Participant must body mass index ( BMI , weight kg divide square height meter ) 18.0 30.0 kilogram per meter^2 ( kg/m2 ) , extremes include Participant must blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic insufficiency , renal dysfunction ( calculated creatinine clearance 60 milliliter per minute ( mL/min ) Screening use CockroftGault equation ) , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers could interfere interpretation study result exclude participant Participants abnormal value either alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ( great equal [ &gt; = ] 1.25 x upper limit laboratory normal range [ ULN ] ) Participants lack good/reasonable venous access Participants past history heart arrhythmia ( extrasystoli , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( example , hypokalemia , family history long QT Syndrome ) Participants history drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 5th edition ) criterion within 5 year Screening positive test result ( ) alcohol and/or drug abuse ( barbiturate , opiate , cocaine , cannabinoids , amphetamine , methadone , benzodiazepine , hallucinogen ) Screening Day 1 treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>